Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
Jinhong Shi, Feiqi Liu, Yanqiu Song Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of ChinaCorrespondence: Yanqiu SongThe First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, Jilin 130021, People’s Republic of ChinaTel +...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/progress-targeted-therapy-immunotherapy-and-new-chemotherapy-strategie-peer-reviewed-article-CMAR |
| _version_ | 1818955657919856640 |
|---|---|
| author | Shi J Liu F Song Y |
| author_facet | Shi J Liu F Song Y |
| author_sort | Shi J |
| collection | DOAJ |
| description | Jinhong Shi, Feiqi Liu, Yanqiu Song Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of ChinaCorrespondence: Yanqiu SongThe First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, Jilin 130021, People’s Republic of ChinaTel +86 18934749569Email song_yq@jlu.edu.cnAbstract: Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, accounting for approximately 15% of cases, and is defined by the lack of expression of hormone receptors (estrogen and progesterone receptors) and lack of amplification or overexpression of human epidermal growth receptor 2 (HER2). Due to the lack of targets of hormone receptors and HER2, treatment of TNBC or advanced TNBC relies on conventional chemotherapeutic agents, but their efficacy and prognosis are poor. In patients with advanced TNBC, poorer outcomes are observed. Recently, with the launch of clinical trials and advancements in molecular studies, targeted therapy for signaling transduction pathways, immunotherapy for immune checkpoints, and new chemotherapy strategies have provided feasible or potential therapeutic options for advanced TNBC. This review aimed to summarize recent progress in targeted therapy, immunotherapy, and chemotherapy for advanced TNBC.Keywords: advanced TNBC, targets, immune checkpoint inhibitor, refractory |
| first_indexed | 2024-12-20T10:41:33Z |
| format | Article |
| id | doaj.art-9b56070f3fd94fc6a80dc90f722dbb3e |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-20T10:41:33Z |
| publishDate | 2020-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-9b56070f3fd94fc6a80dc90f722dbb3e2022-12-21T19:43:32ZengDove Medical PressCancer Management and Research1179-13222020-09-01Volume 129375938757568Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast CancerShi JLiu FSong YJinhong Shi, Feiqi Liu, Yanqiu Song Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of ChinaCorrespondence: Yanqiu SongThe First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, Jilin 130021, People’s Republic of ChinaTel +86 18934749569Email song_yq@jlu.edu.cnAbstract: Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, accounting for approximately 15% of cases, and is defined by the lack of expression of hormone receptors (estrogen and progesterone receptors) and lack of amplification or overexpression of human epidermal growth receptor 2 (HER2). Due to the lack of targets of hormone receptors and HER2, treatment of TNBC or advanced TNBC relies on conventional chemotherapeutic agents, but their efficacy and prognosis are poor. In patients with advanced TNBC, poorer outcomes are observed. Recently, with the launch of clinical trials and advancements in molecular studies, targeted therapy for signaling transduction pathways, immunotherapy for immune checkpoints, and new chemotherapy strategies have provided feasible or potential therapeutic options for advanced TNBC. This review aimed to summarize recent progress in targeted therapy, immunotherapy, and chemotherapy for advanced TNBC.Keywords: advanced TNBC, targets, immune checkpoint inhibitor, refractoryhttps://www.dovepress.com/progress-targeted-therapy-immunotherapy-and-new-chemotherapy-strategie-peer-reviewed-article-CMARadvanced tnbctargetsimmune checkpoint inhibitorrefractory |
| spellingShingle | Shi J Liu F Song Y Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer Cancer Management and Research advanced tnbc targets immune checkpoint inhibitor refractory |
| title | Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer |
| title_full | Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer |
| title_fullStr | Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer |
| title_full_unstemmed | Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer |
| title_short | Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer |
| title_sort | progress targeted therapy immunotherapy and new chemotherapy strategies in advanced triple negative breast cancer |
| topic | advanced tnbc targets immune checkpoint inhibitor refractory |
| url | https://www.dovepress.com/progress-targeted-therapy-immunotherapy-and-new-chemotherapy-strategie-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT shij progresstargetedtherapyimmunotherapyandnewchemotherapystrategiesinadvancedtriplenegativebreastcancer AT liuf progresstargetedtherapyimmunotherapyandnewchemotherapystrategiesinadvancedtriplenegativebreastcancer AT songy progresstargetedtherapyimmunotherapyandnewchemotherapystrategiesinadvancedtriplenegativebreastcancer |